Elan Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.08.12	Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders (Businesswire)
06.08.12	Elan Announces Johnson & Johnson Release of Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) In Mild to Moderate Alzheimer’s Disease (Businesswire)
25.07.12	Elan Reports Second Quarter and First Half 2012 Financial Results (Businesswire)
24.07.12	Elan Announces Pfizer’s Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials (Businesswire)
12.07.12	Elan Announces Webcast of Second Quarter 2012 Financial Results (Businesswire)
11.07.12	Elan-UCD endowment honours Irish business leaders and boosts Ireland’s capacity in the 'Business of Biotechnology' (Businesswire)
28.05.12	Elan to Present at Jefferies 2012 Global Healthcare Conference (Businesswire)
17.05.12	New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine (Businesswire)
27.04.12	Elan to Present at Deutsche Bank 37th Annual Healthcare Conference (Businesswire)
26.04.12	NEW TYSABRI DATA PRESENTED AT 64TH ANNUAL AAN MEETING HIGHLIGHT BIOGEN IDEC & ELAN COMMITMENT TO IMPROVING OUTCOMES IN MULTIPLE SCLEROSIS (Businesswire)
26.04.12	Elan Reports First Quarter 2012 Financial Results (Businesswire)
12.04.12	Elan Announces Webcast of First Quarter 2012 Financial Results (Businesswire)
13.03.12	Elan Raises $381 Million in Sale of 76% of Alkermes Holding (Businesswire)
01.03.12	Elan Chairman Provides Update on CEO Succession (Businesswire)
23.02.12	Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2011 (Businesswire)
21.02.12	Elan to Present at Cowen & Co., 32nd Annual Healthcare Conference (Businesswire)
08.02.12	Elan Reports Fourth Quarter and Full-Year 2011 Financial Results (Businesswire)
01.02.12	Elan to Present at the Leerink Swann 2012 Global Healthcare Conference (Businesswire)
26.01.12	ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis (Businesswire)
20.01.12	FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor (Businesswire)
12.12.11	University College Dublin and Elan Announce Initiative to Create Leadership in Biotechnology (Businesswire)
29.11.11	Elan Provides an Update on ELND005 (Scyllo-inositol) (Businesswire)
28.11.11	Cambridge-Elan Centre for Research Innovation and Drug Discovery Launched (Businesswire)
27.07.11	Elan Reports Second Quarter and First Half 2011 Financial Results (Businesswire)
13.07.11	ShareLuxe Club in Kyoto and Bali Selects Interval International (Businesswire)
01.06.11	Elan to Present at Jefferies 2011 Global Healthcare Conference (Businesswire)
20.04.11	Elan Reports First Quarter 2011 Financial Results (Businesswire)
25.03.11	Elan Announces Filing of Annual Report for Year Ended December 31, 2010 (Businesswire)
13.10.10	Fiserv Announces Closing of Offer to Purchase Its Outstanding 6.125% Senior Notes Due 2012 (Businesswire)
11.01.10	Weltbekannter Yogi Baron Baptiste enthüllt neues Programm, das Menschen mit Multipler Sklerose helfen soll. (Businesswire)
29.10.09	Elan Corporation Plc Announces Expiration of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011 (Businesswire)
27.10.09	Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease (Businesswire)
21.10.09	Elan Reports Third Quarter 2009 Financial Results (Businesswire)
13.07.09	Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid (Businesswire)
23.10.08	Elan Reports Third Quarter 2008 Financial Results (Businesswire)
22.07.08	Biogen Idec und Elan feiern zweiten Jahrestag von TYSABRI(R) zur Behandlung von Multipler Sklerose (Businesswire)
24.04.08	Elan Reports First Quarter 2008 Financial Results (Businesswire)
10.09.07	Scotland Advises TYSABRI(R) Use in Highly Active Relapsing Remitting Multiple Sclerosis (PR Newswire)
09.08.07	Dr. Lars Ekman, President of Research and Development, Transitions to Board of Director Role (Businesswire)
02.07.07	TYSABRI(R) Recommended by NICE for Use in Highly Active Relapsing Remitting Multiple Sclerosis in the Final Appraisal Determination (Businesswire)
24.04.07	Elan Reports First Quarter 2007 Financial Results (Businesswire)
10.04.07	Elan Announces Commencement of Exchange Offer for US$615 Million Aggregate Principal Amount of Notes (Businesswire)
20.02.07	Elan Reports Fourth Quarter and Full-Year 2006 Financial Results (Businesswire)
26.12.06	Seven Summits Research Releases Alerts on F, CVS, ELN, PGR, and LTD (PR Newswire)
22.11.06	Elan Announces Completion of Offering of US$615 Million Aggregate Principal Amount of Senior Notes (Businesswire)
06.10.06	New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis (Businesswire)
29.09.06	Neue Daten belegen auf dem MS-Kongress ECTRIMS bedeutende Verbesserungen der kognitiven Fähigkeiten bei Patienten mit Multipler Sklerose (Businesswire)
28.09.06	New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis (Businesswire)
01.08.06	Elan Reports Second Quarter 2006 Financial Results (Businesswire)
24.07.06	Biogen Idec und Elan geben Lieferbarkeit von TYSABRI(R) zur Behandlung wiederkehrender Formen von multipler Sklerose bekannt (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	93.70	1.32 %	K V
Sika	243.20	1.16 %	K V
Part Grp Hldg	1’422.50	1.07 %	K V
Givaudan	3’986.00	1.06 %	K V
Holcim	99.22	1.00 %	K V
Alcon	81.52	-0.49 %	K V
Roche Hldg G	295.70	-0.71 %	K V
Zurich Insur Gr	565.20	-0.74 %	K V
Novartis	96.70	-1.10 %	K V
Swisscom	501.50	-1.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Elan Corporation PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten